Breakfast and lunch and even dinner tasted a lot better to the executives of Allergen as the news leaked out that Medicis Pharmaceutical received a rejection letter from the FDA on their application for Reloxin. The FDA stated that the application was incomplete.
The rejection comes as Medicis was expecting to be able sell Reloxin by the end of this year. According to a Medicis filing with the SEC, the FDA letter addressed administrative deficiencies and did not reference any substantive deficiencies.
